Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F annual reports and Form 6‑K current reports. This SEC filings page on Stock Titan centralizes those documents and pairs them with AI‑generated summaries to help readers understand the regulatory information associated with Immuron’s biopharmaceutical business.
Recent Form 6‑K filings furnished by Immuron reference Australian Securities Exchange announcements such as applications for quotation of securities, cleansing notices, CEO addresses, annual general meeting results, changes of director interests, changes of share registry, and clinical and regulatory milestones including FDA approval of the IMM‑529 Investigational New Drug application. These filings provide context on capital management, governance decisions and progress in the company’s clinical programs for Travelan/IMM‑124E, IMM‑529 and IMM‑986.
On this page, you can review Immuron’s 20‑F annual report for a comprehensive description of its operations, risk factors and financial statements, and browse 6‑K current reports that capture material information first released to the Australian Securities Exchange. Where applicable, Stock Titan also surfaces Form 4 and related insider transaction disclosures that are filed in connection with changes in director or executive holdings, as referenced in Immuron’s 6‑K exhibits.
Stock Titan’s AI features highlight key points from lengthy filings, explain technical sections in plain language, and help you locate items such as clinical trial updates, securities issuances and shareholder meeting outcomes. This makes it easier to track how Immuron’s regulatory disclosures align with its strategy in orally delivered targeted polyclonal antibodies and its commercial and clinical activities.
Immuron Limited has called an Extraordinary General Meeting for 12 February 2026 to seek shareholder approval to ratify prior share issues made under its at-the-market (ATM) funding facility. Shareholders are being asked to approve two resolutions ratifying the issue of 28,278,923 shares under ASX Listing Rule 7.1 and 26,821,997 shares under Listing Rule 7.1A, for a total of 55,100,920 fully paid ordinary shares. The shares were issued in several ATM drawdowns in October, November and December 2025 at prices between $0.07560 and $0.08860 per share.
The company previously filed a Form F-3 and ATM prospectus in the United States allowing it to raise up to US$15 million over three years, and later extended the ATM facility by an additional approximate aggregate offering price of US$2,847,954. Funds raised are intended to support working capital and various projects. The board unanimously recommends that shareholders vote in favour of both ratification resolutions.
Immuron Limited furnished a Form 6-K to provide U.S. investors with copies of two announcements it filed with the Australian Securities Exchange. The announcements, dated December 16, 2025, are an Application for quotation of securities and a related Cleansing Notice, both attached as exhibits to the report.
Immuron Limited submitted a Form 6-K as a foreign private issuer for December 2025. The company is furnishing to U.S. investors two announcements it released to the Australian Securities Exchange on December 15, 2025, including an application for quotation of securities and a cleansing notice.
The materials are provided as exhibits to the Form 6-K and are expressly stated not to be treated as filed for Exchange Act purposes or automatically incorporated into other U.S. securities filings unless specifically referenced.
Immuron Limited submitted a report as a foreign private issuer to share information it had already released on the Australian Securities Exchange. The report attaches two December 11, 2025 ASX announcements: an application for quotation of securities and a cleansing notice. These documents are furnished to U.S. regulators for information purposes and are not automatically incorporated into other U.S. securities law filings unless specifically referenced later.
Immuron Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an announcement it released to the Australian Securities Exchange. The attached exhibit, titled “Uniformed Services University to Release Topline Data,” is included as Exhibit 99.1.
The company clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will not be incorporated into other U.S. securities filings unless specifically referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer for December 2025 to furnish an announcement made to the Australian Securities Exchange. The filing explains that the company published a public notice on December 4, 2025 titled “Change of Share Registry,” which is attached as Exhibit 99.1. The Form 6-K specifies that this information is being furnished, not filed, under U.S. securities laws and will not be incorporated into other securities law filings unless specifically referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer for November 2025. The company is furnishing to U.S. investors copies of two announcements it filed with the Australian Securities Exchange on November 7, 2025: an application for quotation of securities and a cleansing notice.
These Australian announcements are attached to the Form 6-K as exhibits 99.1 and 99.2. The company notes that this Form 6-K, including the exhibits, is being furnished rather than filed and will only be incorporated into other U.S. securities filings if specifically referenced.
Immuron Limited furnished a Form 6-K announcing that it has attached an Australian Securities Exchange notice titled “Proposed issue of securities - IMC.” The filing provides the ASX public notice as Exhibit 99.1 for U.S. investors’ awareness.
The submission is an information update and does not include financial results or transaction terms. It primarily serves to make the ASX announcement available to the U.S. market.